Latest Breaking News On - Betsy brod - Page 6 : vimarsana.com

Virpax Pharmaceuticals: Virpax to Initiate Investigational New Drug (IND) Enabling Studies for Epoladerm BERWYN, PA / ACCESSWIRE / March 10, 2021 / Virpax ® Pharmaceuticals Inc. ( Virpax or the Company ) (NASDAQ:VRPX), today announced that it has signed an agreement with Charles River Laboratories to initiate preclinical studies of Epoladerm, Virpax s proprietary, patented, anti-inflammatory topical spray film delivery technology for acute musculoskeletal pain. Under the terms of this agreement, Charles River Laboratories will perform seven preclinical animal studies including method, dosage, and toxicity as part of the required U.S. Food and Drug Administration ( FDA ) enabling trials for an Investigational New Drug Application ( IND ) for Epoladerm.

Kostenloser wertpapierhandelAnthony mackBetsy brodChristopherm chipmanJeff gudinExchange commissionVirpax pharmaceuticalsSecurities exchangeDrug administrationMolecular envelope technologyPharmaceuticals incCharles river laboratoriesInvestigational new drug applicationChief executive officerChief medical officerDiclofenac epolamine